Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
Novartis and Bristol Myers have paused CAR-T trials after patient deaths, raising safety concerns in the biopharma industry.
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 14.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
Source diversity sample: FirstWord Pharma · BioPharma Dive · Fierce Biotech · WSJ · Endpoints News.
How this dossier is built: methodology · AI policy · corrections.
The reporting (5)
- Novartis pauses immunology, neuro CAR-T studies after three patient deaths FirstWord Pharma · 6h ago
- Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns BioPharma Dive · 6h ago
- UPDATED: Novartis halts autoimmune CAR-T trials after 3 deaths, as BMS also pauses studies Fierce Biotech · 6h ago
- Novartis Pauses Autoimmune Cell Therapy Studies After Deaths WSJ · 6h ago
- Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused Endpoints News · 6h ago
What happened
Novartis and Bristol Myers have paused clinical trials for CAR-T therapies targeting autoimmune diseases. The halt follows three patient deaths in Novartis's trials. The pause affects multiple studies in both companies' pipelines. The pause comes after three deaths in Novartis's CAR-T trials.
Bristol Myers has also paused its autoimmune CAR-T programs. The halt affects multiple studies in both companies' pipelines. The companies have not yet disclosed details about the deaths or the specific trials involved. The pause raises questions about the safety of CAR-T therapies for autoimmune diseases.
CAR-T therapies have shown promise in treating certain cancers, but their use in autoimmune diseases is still in early stages. The pause by Novartis and Bristol Myers may slow down the development of these therapies, but it also underscores the importance of safety in clinical trials.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 2h ago.
Questions people are asking
Which companies are affected by the pause in CAR-T trials?
Novartis and Bristol Myers have both paused their CAR-T trials for autoimmune diseases.
How many deaths occurred in the Novartis trials?
Three deaths occurred in Novartis's CAR-T trials.
What is the status of Bristol Myers's CAR-T programs?
Bristol Myers has paused its autoimmune CAR-T programs.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Topics
Related trends
BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test
BioNTech and Roche have halted a mid-stage cancer vaccine trial after more deaths occurred in the treatment group than in the control group.
SINGLE-AF: DOAC Therapy vs. No Anticoagulation in AFib Patients at Intermediate Risk For Stroke
A major clinical trial has yielded surprising results about the use of anticoagulants in atrial fibrillation patients.
In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs
AstraZeneca and Ionis' failed heart disease trial raises questions about the future of RNA drugs
Cell therapy substantially reduces severe rheumatoid arthritis in first clinical trial
First CAR‑T trial signals remission for severe rheumatoid arthritis, sparking hope for an immune reset.
Bristol Myers ends deal with Cellares, cell therapy manufacturer to reorg
Bristol Myers Squibb ends blood‑cancer deal, prompting Cellares to cut 100 jobs and reorganize.
Vacant lab space, shrinking workforce put Mass. in ‘unique position’ for biotech bounceback
Massachusetts' biotech sector faces a paradox: job losses amid a rebound in investment.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.